Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 2630 clinical trials
A081801 / RLUN20119 / ALCHEMIST-IO (ACCIO) / Yuhchyau Chen  

This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and …

  • 0 views
  • 19 Feb, 2024
  • 1 location
Role of Lymphnode Dissection in Men With Prostate Cancer Treated With Radical Prostatectomy

This is particularly of interest considering the rapidly advancing technical possibilities, both in imaging and in the treatment of prostate cancer, since this enables an earlier and more individual intervention in the case of recurrence.

endocrine therapy
metastasis
hormone therapy
cancer
lymphadenectomy
  • 0 views
  • 19 Feb, 2024
bpMRI and Risk Based Shared Clinical Decision Making in Prostate Cancer Diagnosis

Therefore, the primary objective of this trial is to compare if there is a difference between significant cancer detection rate in men undergoing prostate biopsies after MRI scan compared to men undergoing post-MRI prostate biopsies only after a shared decision-making based on prostate cancer risk estimation. The trial will enrol …

biopsy of prostate
cancer diagnosis
digital rectal examination
  • 0 views
  • 19 Feb, 2024
The Impact of Low Pressure Pneumo in RARP II

The purpose of this study is to evaluate clinical significance of low pressure pneumoperitoneum during robotically assisted radical prostatectomy (RARP).

prostatectomy
  • 0 views
  • 19 Feb, 2024
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT …

bone disease
progressive disease
lymphadenopathy
endocrine therapy
metastatic castration-resistant prostate cancer
  • 0 views
  • 19 Feb, 2024
Prostate Screening for Men With Inherited Risk of Developing Aggressive Prostate Cancer PATROL Study

This study investigates ways to detect prostate cancer earlier in men who are at increased genetic risk of developing prostate cancer that forms, grows, or spreads quickly (aggressive).

carcinoma
cancer
prostate cancer
digital rectal exam
BRCA1
  • 0 views
  • 19 Feb, 2024
CT-guided Stereotactic Body Radiation Therapy and MRI-guided Stereotactic Body Radiation Therapy for Prostate Cancer MIRAGE Study

This phase III trial studies compares CT-guided stereotactic body radiation therapy and MRI-guided stereotactic body radiation therapy (SBRT) in treating prostate cancer. Image-guided SBRT is a standard treatment for prostate cancer, which combines imaging of the cancer within the body with the delivery of therapeutic radiation doses produced on a …

MRI
metastasis
positron emission tomography
ct scan
stereotactic body radiation therapy
  • 0 views
  • 19 Feb, 2024
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of AB928-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

combined modality therapy
prostatic neoplasms, castration-resistant
docetaxel
testosterone
cancer
  • 0 views
  • 19 Feb, 2024
Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Evaluate the safety and tolerability of AMG 509 in adult subjects and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

liver metastasis
progressive disease
metastatic castration-resistant prostate cancer
metastasis
abiraterone
  • 0 views
  • 19 Feb, 2024
5 Fractions of Pelvic SABR With Intra Prostatic SABR Boost:

5-fraction SABR is a feasible, well-tolerated, effective and cost effective treatment for high-intermediate and high risk prostate cancer with/without an image-guided intraprostatic boost.

stereotactic body radiation therapy
adenocarcinoma
adenocarcinoma of prostate
  • 0 views
  • 19 Feb, 2024